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Background: The ability of an intermittent fasting (IF)-calorie restriction (CR) regimen (with or without liquid meals)
to modulate adipokines in a way that is protective against coronary heart disease (CHD) has yet to be tested.
Objective: Accordingly, we examined the effects of an IFCR diet on adipokine profile, body composition, and
markers of CHD risk in obese women.
Methods: Subjects (n = 54) were randomized to either the IFCR-liquid (IFCR-L) or IFCR-food based (IFCR-F) diet for
10 weeks.
Results: Greater decreases in body weight and waist circumference were noted in the IFCR-L group (4 ± 1 kg; 6 ± 1 cm)
versus the IFCR-F group (3 ± 1 kg; 4 ± 1 cm). Similar reductions (P < 0.0001) in fat mass were demonstrated in the
IFCR-L (3 ± 1 kg) and IFCR-F group (2 ± 1 kg). Reductions in total and LDL cholesterol levels were greater (P = 0.04)
in the IFCR-L (19 ± 10%; 20 ± 9%, respectively) versus the IFCR-F group (8 ± 3%; 7 ± 4%, respectively). LDL peak
particle size increased (P < 0.01) in the IFCR-L group only. The proportion of small LDL particles decreased (P < 0.01)
in both groups. Adipokines, such as leptin, interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and
insulin-like growth factor-1 (IGF-1) decreased (P < 0.05), in the IFCR-L group only.
Conclusion: These findings suggest that IFCR with a liquid diet favorably modulates visceral fat and adipokines in a
way that may confer protection against CHD.
Keywords: Intermittent fasting, Calorie restriction, Liquid diet, Body weight, Visceral fat, Cholesterol, Coronary heart
disease, Obese womenIntroduction
Intermittent fasting (IF) is a novel weight loss regimen
that has been steadily growing in popularity over the
past decade [1]. This diet strategy generally involves se-
vere restriction (75-90% of energy needs) on 1–2 days
per week. Though clinical trial evidence is still limited
[2,3], preliminary findings indicate that IF may be effect-
ive for weight loss and coronary heart disease (CHD)
risk reduction. For instance, two recent trials of IF* Correspondence: varady@uic.edu
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reproduction in any medium, provided the ordemonstrate decreases in body weight of 7-9% and
reductions in LDL cholesterol of 10% after 20–24 weeks
of treatment [2,3]. While these data are encouraging,
this diet therapy is limited in that a long duration of
time, i.e. 24 weeks, is required to experience modest
reductions in weight. One possible way to boost the rate
of weight loss would be to combine IF with daily calorie
restriction (CR). In following this protocol, the individ-
ual would fast one day per week, and then undergo mild
CR, i.e. 20% restriction of energy needs, on 6 days per
week. The incorporation of portion-controlled liquid
meals may also enhance weight loss as it helps indivi-
duals to stay within the confines of their prescribedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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(with or without liquid meals) on body weight and CHD
risk has yet to be tested.
Although the mechanisms remain unclear, the lipid-
lowering actions of dietary restriction protocols may
be mediated, in part, by modulations in adipokines, i.e.
fat-cell derived hormones and cytokines [6]. Leptin is
an adipokine that plays a role in CHD development by
increasing platelet aggregation [7], and stimulating the
proliferation and migration of endothelial cells [8].
Interleukin-6 (IL-6) and tumor necrosis factor-alpha
(TNF-alpha) are pro-inflammatory mediators released
by adipose tissue that are strong independent predic-
tors of CHD [9]. C-reactive protein (CRP) is produced
by adipose tissue in response to a rise in IL-6 [10].
CRP may play a role in atherogenesis by binding to
oxidized LDL and promoting foam cell formation [11].
Isoprostanes are another group of compounds released
by adipose tissue [12]. Isoprostanes act as markers of
oxidative stress, and have been shown to accumulate
in atherosclerotic lesions of carotid arteries derived
from CHD patients [12]. Insulin-like growth hormone-
1 (IGF-1), another adipose tissue-derived protein, may
play a role in the development of CHD by stimulating
the proliferation of vascular smooth muscle cells [13].
Circulating concentrations of these hormones are dic-
tated by regional fat distribution [14]. Excess visceral
adiposity, as determined by an increased waist circum-
ference, is related to an increased incidence of dyslipi-
demia [14]. Viscerally obese women (defined as a waist
circumference >88 cm) have higher circulating levels
of each of the above-mentioned adipokines, relative to
subcutaneously obese women [15]. The ability of IFCR
to reduce visceral fat mass, and in turn, improve circulating
adipokine profile, remains unknown.
Accordingly, the objective of the present study was to
examine the effect of IFCR with a liquid-diet or food
based diet on body weight and lipid risk factors for CHD
in obese women, and to evaluate how changes in adipo-




Obese women were recruited from the Chicago area by
means of advertisements placed on and around the
University of Illinois campus. Seventy-seven individuals
responded to the advertisements, and 60 were deemed
eligible to participate after the preliminary question-
naire, body mass index (BMI) and waist circumference
assessment. Key inclusion criteria were as follows: female,
age 35–65 y, BMI between 30 and 39.9 kg/m2, waist cir-
cumference >88 cm, weight stable for 3 months prior to
the beginning of the study, i.e. <5 kg weight loss or gain,non-diabetic, no history of cardiovascular disease, no his-
tory of cancer, sedentary or lightly active for 3 months
prior to the beginning of the study, i.e. <3 h/week of
light-intensity exercise at 2.5–4.0 metabolic equivalents
(METS), non-smoker, and not taking weight loss,
lipid-lowering, or glucose-lowering medications. Peri-
menopausal women were excluded from the study, and
postmenopausal women (defined as absence of menses
for 2 y) were required to maintain their current hormone
replacement therapy regimen for the duration of the
study. The experimental protocol was approved by the
Office for the Protection of Research Subjects at the
University of Illinois, Chicago, and all volunteers gave
written informed consent to participate in the trial.
Diet interventions
Subjects were randomized by way of a stratified random
sample, based on BMI and age, into either the IFCR-
liquid diet (IFCR-L) group (n = 30) or IFCR-food based
diet (IFCR-F) group (n = 30). A random number table
was used to randomize the subjects from each strata into
the intervention groups. The 10-week trial consisted of
two dietary phases: 1) a 2-week baseline weight mainten-
ance period, and 2) an 8-week weight loss period.
Baseline weight maintenance diet (Week 1–2)
Each subject participated in a 2-week baseline weight
maintenance period before commencing the 8-week
weight loss intervention (Figure 1). During this period,
subjects were requested to continue eating their usual
diet and to maintain a stable body weight.
Weight loss diets (Week 3–10)
After the baseline period, subjects partook in either the
IFCR-L or IFCR-F intervention for 8 weeks (Figure 1).
The Mifflin equation was used to measure energy
requirements [16]. IFCR-L subjects (n = 30) consumed a
calorie-restricted liquid diet for the first 6 days of the
week, and then underwent a fast on the last day of the
week (water consumption + 120 kcal of juice powder
only, for 24 h). The liquid diet consisted of a liquid meal
replacement for breakfast (240 kcal) and a liquid meal
replacement for lunch (240 kcal). All liquid meal repla-
cements were provided to the subjects in powder-form
in premeasured envelopes (Isalean Shake, Isagenix LLC,
Chandler, AZ). For the dinnertime meal, IFCR-L subjects
consumed a 400–600 kcal meal. Food was not provided
to the subjects for the dinner meal. Instead, subjects met
with a Registered Dietician weekly to learn how to make
healthy eating choices that are in compliance with the
National Cholesterol Education Program Therapeutic
Lifestyle Changes (TLC) diet (i.e. <35% of kcal as fat;
50-60% of kcal as carbohydrates; <200 mg/d of dietary
cholesterol; and 20–30 g/d of fiber). In following this
Figure 1 Experimental design.
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by 30% of their baseline needs. IFCR-F subjects (n = 30)
consumed a calorie-restricted food-based diet for the
first 6 days of the week, and then underwent a fast on the
last day of the week (water consumption + 120 kcal of
juice powder only, for 24 h). IFCR-F subjects ate 3 meals
per day in accordance with the TLC diet guidelines. Food
was not provided to the subjects. Instead, subjects met
with a Registered Dietician weekly to learn how to make
healthy eating choices by implementing the TLC guide-
lines. Subjects were instructed to eat approximately 240
kcal for breakfast, 240 kcal for lunch, and 400–600 kcal
for dinner. In following this 7 d intervention, IFCR-F
subjects were energy restricted by 30% of their baseline
needs.
Analyses
Dietary intake and physical activity assessment
A multiple-pass, telephone-administered, 24-h recall was
used to assess dietary intake. The recalls were performed
at weeks 1, 3 and 10 by a trained Registered Dietician.
Dietary intake data were analyzed using Nutrition Data
System (NDS) software (version 2012; University of Min-
nesota, Minneapolis, MN). Furthermore, IFCR-L subjects
were provided with a checklist each day to monitor: 1)
adherence to the liquid meal protocol, and 2) adherence
to the fast day regimen. IFCR-F subjects were also given
a checklist to monitor their adherence to the fast day
regimen. Alterations in energy expenditure associated
with changes in physical activity were measured by the
use of a pattern recognition monitor (Sense Wear Mini
(SWM), Bodymedia, Pittsburgh, PA). Subjects wore the
lightweight monitor on their upper arm for 7 d at
week 3 and 10 of the trial. The data was analyzed
using Bodymedia Software V.7.0, algorithm V.2.2.4
(Bodymedia, Pittsburgh, PA).
Hunger, satisfaction, and fullness assessment
Subjects completed a validated visual analog scale (VAS)
on each fast day approximately 5 min before going to
bed (reported bedtime ranged from 8.00 pm to 1.20 am).
In brief, the VAS consisted of 100-mm lines, and sub-
jects were asked to make a vertical mark across the line
corresponding to their feelings from 0 (not at all) to 100
(extremely) for hunger, satisfaction with diet, or fullness.The VAS was collected at the weigh-in each week and
reviewed for completeness. Quantification was per-
formed by measuring the distance from the left end of
the line to the vertical mark.
Body weight and body composition assessment
Body weight measurements were taken to the nearest
0.5 kg at the beginning of every week in light clothing
and without shoes using a balance beam scale (Health-
OMeter; Sunbeam Products, Boca Raton, FL). Height
was assessed using a wall-mounted stadiometer to the
nearest 0.1 cm. BMI was assessed as kg/m2. Fat mass
and fat free mass were assessed by dual energy X-ray
absorptiometry (DXA) at weeks 1, 3 and 10 (QDR
4500 W, Hologic Inc. Arlington, MA). Waist circum-
ference was measured by a flexible tape to the nearest
0.1 cm, midway between the lower costal margin and
super iliac crest during a period of expiration.
Plasma lipids and adipokine assessment
Fasting blood samples were collected between 6.00 am
and 9.00 am at weeks 1, 3 and 10 after a 12-h fast. Blood
was centrifuged for 10 min at 520 × g at 4°C to separate
plasma from red blood cells and was stored at −80°C
until analyzed. Plasma total cholesterol, direct LDL chol-
esterol, HDL cholesterol, and triglyceride concentrations
were measured in duplicate by enzymatic kits (Biovision
Inc, Mountainview, CA). LDL particle size was measured
by linear polyacrylamide gel electrophoresis (Quantime-
trix Lipoprint System, Redondo Beach, CA), as previously
described [17]. Leptin, IL-6, TNF-alpha, CRP, 8-isopros-
tane, and IGF-1 were assessed in duplicate at week 1, 3,
and 10 by ELISA (R&D Systems, Minneapolis, MN).
Statistics
Results are presented as mean ± SEM. Sample size was
calculated as n = 30 subjects per group, assuming a 5%
decrease in body weight in the IFCR-L group, with a
power of 80% and an α risk of 5%. An independent sam-
ples t-test was used to test baseline differences between
groups. Repeated-measures ANOVA was performed,
taking time as the within-subject factor and diet as the
between-subject factor, to assess differences between
groups over the course of the study. Post-hoc analyses
were performed using the Tukey test. Differences were
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using SPSS software (version 20.0, SPSS Inc, Chicago, IL).
Results
Subject dropout and baseline characteristics
Sixty subjects (IFCR-L n = 30, IFCR-F n = 30) commenced
the study. Two subjects dropped out of the IFCR-L group
due to scheduling conflicts (n = 1) and problems adhering
to the diet (n = 1). Four subjects dropped out of the IFCR-
F group because of scheduling conflicts (n = 2) and inabil-
ity to adhere to the diet protocol (n = 2). Thus, a total of
28 and 26 subjects completed the IFCR-L and IFCR-F
interventions, respectively. There were no differences be-
tween groups for age, ethnicity, or BMI (Table 1).
Dietary intake and physical activity
Diet and physical activity data are displayed in Table 2.
Adherence to the fast day protocol was similar between
groups (P = 0.91) (IFCR-l: 96 ± 4% compliance; IFCR-F:
98 ± 3% compliance). Compliance with the liquid meal
protocol was 92 ± 3% in the IFCR-L group over the
course of the 8 weeks. Energy intake decreased (P < 0.05)
in both the IFCR-L and IFCR-F groups between week 3
and 10. There were no changes in fat, protein, carbohy-
drate, cholesterol, or fiber intake from the beginning to
the end of the study in either group. Activity expenditure
and steps/d remained stable over the course of the trial in
both intervention groups. Hours of sleep per night also
did not change during the 8-week weight loss period in
either the IFCR-L or IFCR-F group.
Hunger, satisfaction, and fullness assessment
Hunger scores were low, and did not differ over the
course of the trial in the IFCR-L (week 3: 27 ± 8 mm,
week 10: 28 ± 7 mm) or IFCR-F group (week 3: 46 ± 7
mm, week 10: 39 ± 7 mm). Satisfaction with the diets
remained elevated from the beginning to the end of theTable 1 Subject characteristics at baseline1
Characteristic IFCR-L IFCR-F
n 28 26
Age (y) 47 ± 2 48 ± 2
Ethnicity




Body weight (kg) 95 ± 3 94 ± 3
Height (cm) 165 ± 2 164 ± 2
Body mass index (kg/m2) 35 ± 1 35 ± 1
1 Values reported as mean ± SEM. IFCR-L: Intermittent fasting calorie
restriction-liquid diet; IFCR-F: Intermittent fasting calorie restriction-food based
diet. No differences between groups for any parameter (Independent
samples t-test).study in the IFCR-L (week 3: 72 ± 7 mm, week 10: 78 ±
6 mm) and IFCR-F group (week 3: 55 ± 9 mm, week 10:
66 ± 6 mm). Fullness scores were moderate and stable
during the trial in the IFCR-L (week 3: 66 ± 7 mm, week
10: 82 ± 6 mm) or IFCR-F group (week 3: 58 ± 7 mm,
week 10: 64 ± 6 mm). No differences were noted be-
tween groups for hunger, satisfaction or fullness at either
time point.Body weight and body composition
Changes in body weight and body composition are
reported in Table 3. Body weight remained stable in both
the IFCR-L group (week 1: 95 ± 3, week 3: 95 ± 3 kg) and
IFCR-F group (week 1: 94 ± 3, week 3: 94 ± 3 kg) during
the weight maintenance period. Body weight decreased to
a greater extent (P < 0.05) in the IFCR-L group (4 ± 1 kg)
versus the IFCR-F group (3 ± 1 kg) during the weight loss
period. Similar decreases (P < 0.0001) in fat mass were
observed in the IFCR-L (3 ± 1 kg) and IFCR-F (2 ± 1 kg)
groups after 8 weeks of treatment. Fat free mass remained
unchanged throughout the course of the trial in both
groups. Greater decreases (P < 0.05) in waist circumfer-
ence were demonstrated in the IFCR-L (6 ± 1 cm) when
compared to the IFCR-F group (4 ± 1 cm). BMI decreased
(P < 0.0001) by 1 ± 1 and 1 ± 1 kg/m2, respectively, in the
IFCR-L and IFCR-F groups.Plasma lipids and adipokines
Changes in plasma lipid concentrations and LDL particle
size are displayed in Figure 2. Total and LDL cholesterol
concentrations were reduced (P < 0.05) to a greater
extent in the IFCR-L group (19 ± 10%; 20 ± 9%, respect-
ively) compared to the IFCR-F group (8 ± 3%; 7 ± 4%,
respectively). HDL cholesterol was not changed by either
diet. Triglycerides decreased (P < 0.0001) in the IFCR-L
group only (17 ± 9%). LDL peak particle size increased
(P < 0.01) in the IFCR-L group only, while the propor-
tion of small particles was reduced (P < 0.05) in the both
the IFCR-L and IFCR-F groups. Changes in adipokines
are reported in Table 4. Leptin decreased (P < 0.05) to a
similar extent in the IFCR-L (−9 ± 2 ng/ml) and the
IFCR-F group (−8 ± 2 ng/ml). IL-6, TNF-alpha, and
IGF-1 concentrations were reduced (P < 0.05) in the
IFCR-L group only. Significant associations between
plasma lipids and adipose tissue parameters were noted
in the IFCR-L group only. For instance, decreases in
LDL cholesterol were related to reductions in waist circum-
ference (r = 0.26, P = 0.04), and leptin (r = 0.37, P = 0.04).
Reductions in triglycerides were also related to
decreased leptin (r = 0.29, P = 0.04) and TNF-alpha
(r = 0.33, P = 0.03). Furthermore, decreased waist cir-
cumference was related to lower circulating leptin
levels (r = 0.45, P = 0.03).
Table 2 Dietary intake and physical activity during the weight loss period1
IFCR-L IFCR-F
Diet variables Week 3 Week 10 Change 2 Week 3 Week 10 Change 2
Energy (kcal) 1708 ± 135 1255 ± 102 3 −453 ± 210 1694 ± 180 1444 ± 132 3 −250 ± 146
Total fat (g) 54 ± 6 51 ± 11 −3 ± 14 62 ± 9 47 ± 5 −15 ± 11
Saturated fat (g) 20 ± 2 18 ± 3 −2 ± 4 22 ± 4 18 ± 2 −4 ± 4
Monounsaturated fat (g) 22 ± 2 17 ± 3 −5 ± 5 26 ± 4 17 ± 1 −9 ± 4
Polyunsaturated fat (g) 12 ± 2 16 ± 5 4 ± 6 14 ± 2 12 ± 2 −2 ± 3
Protein (g) 75 ± 5 84 ± 12 9 ± 14 67 ± 6 65 ± 9 −2 ± 4
Carbohydrates (g) 226 ± 20 215 ± 49 −11 ± 60 210 ± 23 174 ± 20 −36 ± 20
Cholesterol (mg) 215 ± 27 196 ± 36 −19 ± 51 224 ± 43 169 ± 28 −55 ± 53
Fiber 17 ± 1 23 ± 7 6 ± 8 20 ± 2 16 ± 2 −4 ± 2
Physical activity variables Week 3 Week 10 Change 2 Week 3 Week 10 Change 2
Activity expenditure (kcal/d) 249 ± 28 283 ± 27 34 ± 76 246 ± 37 258 ± 43 12 ± 25
Steps (steps/d) 6975 ± 526 7375 ± 426 400 ± 261 5876 ± 621 6405 ± 599 529 ± 610
Sleep (h/d) 6.4 ± 0.4 6.0 ± 0.2 −0.4 ± 1.0 6.2 ± 0.5 5.5 ± 0.4 0.7 ± 0.5
1 Values reported as mean ± SEM. IFCR-L: IFCR-L: Intermittent fasting calorie restriction-liquid diet (n = 28); IFCR-F: Intermittent fasting calorie restriction-food
based diet (n = 26).
2 Change expressed as the difference between week 3 and week 10 absolute values.
3 Week 3 values significantly (P < 0.05) different from week 10 values within group (Repeated-measures ANOVA).
No significant difference between groups for any nutrient except energy.
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This study is the first to show that IFCR with liquid
meals can produce potent decreases in CHD risk, and
that these effects are mediated in part by improvements
in adipokines. More specifically, we show here that
IFCR-L is an effective diet therapy to modulate lipid
indicators of CHD risk, i.e. reduce LDL cholesterol, tri-
glycerides, and the proportion of small LDL particles,
while increasing LDL peak particle size. Our findings
also demonstrate that these favorable changes in lipids
were related to reduced waist circumference (visceral fat
mass) and reductions in pro-atherogenic adipokines,
such as leptin and TNF-alpha.
Although both of the interventions produced favorable
changes in lipids, superior modulations were shown in
the IFCR-L group when compared to the IFCR-F group.
The reductions in plasma lipids by IFCR-L (LDL-Table 3 Body weight and body composition changes during t
IFCR-L
Week 3 Week 10
Body weight (kg) 95 ± 3 91 ± 3 3
Fat mass (kg) 45 ± 1 42 ± 1 3
Fat free mass (kg) 50 ± 1 49 ± 2
Waist circumference (cm) 103 ± 1 97 ± 1 3
Body mass index (kg/m2) 35 ± 1 34 ± 1 3
1 Values reported as mean ± SEM. IFCR-L: IFCR-L: Intermittent fasting calorie restrict
based diet (n = 26).
2 Change expressed as the difference between week 3 and week 10 absolute value
3 Week 3 values significantly (P < 0.05) different from week 10 values within group
4 Absolute change significantly different (P < 0.05) between the IFCR-L and IFCR-F gcholesterol: 19%, triglycerides: 20%) are similar to what
has been reported in previous trials of IF [2,3]. For in-
stance, in a trial by Williams et al. [3], obese subjects
consumed a very-low calorie diet (VLCD; <500 kcal/d) 1
day per week, and ate ad libitum every other day of the
week. After 20 weeks of treatment, LDL cholesterol
and triglyceride concentrations decreased by 10% and
52%, respectively [3]. In the trial by Harvie et al. [2],
obese women underwent 2 days of VLCD (600 kcal/d)
and ate ad libitum on every other day of the week, for
24 weeks. Post-treatment LDL cholesterol and trigly-
ceride levels were reduced by 10% and 17% from base-
line [2]. The mechanism by which IFCR modulates
circulating lipid concentrations is not clear. Nonethe-
less, recent evidence from CR studies indicate that the
oxidation of circulating free fatty acids (FFA) is increased
during periods of weight loss, while FFA synthesis ishe weight loss period1
IFCR-F
Change 2 Week 3 Week 10 Change 2
−4 ± 1 4 94 ± 2 91 ± 2 3 −3 ± 1
−3 ± 1 45 ± 1 43 ± 1 3 −2 ± 1
−1 ± 1 49 ± 1 48 ± 1 −1 ± 1
−6 ± 1 4 102 ± 3 98 ± 3 3 −4 ± 1
−1 ± 1 35 ± 1 34 ± 1 3 −1 ± 1




Figure 2 Changes in lipid indicators of coronary heart disease risk during the weight loss period. Values reported as mean ±SEM change
between week 3 and 10. IFCR-L: Intermittent fasting calorie restriction-liquid diet (n = 28); IFCR-F. Intermittent fasting calorie restriction-food
based diet (n = 26). A. Total cholesterol. B. LDL cholesterol. C. HDL cholesterol. D. Triglycerides. E. LDL peak particle size. F. Proportion of small
LDL particles. *Week 3 values significantly (P < 0.05) different from week 10 values within E group (Repeated-measures ANOVA). # Significantly
different (P < 0.05) between the IFCR-L and IFCR-F group (Repeated-measures ANOVA).
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results in a reduction in hepatic synthesis and secretion
of very-low density lipoprotein (VLDL) into plasma.
Lower secretion of VLDL contributes to reduced plasma
concentrations of LDL, since VLDL is quickly converted
to LDL in the circulation [19]. Although this mechanism
has only been demonstrated for CR, it possible that IFCR
may alter circulating lipids in a similar fashion.
The greater improvement in lipid profile by IFCR-L is
most likely due to the more pronounced reductions in
body weight and visceral fat mass observed. After 8
weeks of treatment, body weight and waist circumfer-
ence, an indirect indicator of visceral fat, decreased to a
greater extent in the IFCR-L (4 kg and 6 cm, respect-
ively) when compared to the IFCR-F group (3 kg and 4
cm, respectively). The greater weight loss by the IFCR-L
group is not surprising as these individuals had a largerTable 4 Changes in adipokines during the weight loss period
IFCR-L
Week 3 Week 10
Leptin (ng/ml) 36.5 ± 2.5 27.1 ± 3.1 3
IL-6 (pg/ml) 3.1 ± 0.3 2.5 ± 0.3 3
TNF-alpha (pg/ml) 1.6 ± 0.3 1.2 ± 0.3 3
C-Reactive protein (mg/dl) 0.4 ± 0.1 0.4 ± 0.1
8-isoprostane (pmol/mg) 1.8 ± 0.1 1.9 ± 0.1
IGF-1 (ng/ml) 67.7 ± 3.8 60.8 ± 4.2 3
1 Values reported as mean ± SEM. IFCR-L: Intermittent fasting calorie restriction-liqu
(n = 26). IL-6: Interleukin-6, TNF-alpha: Tumor necrosis factor-alpha, IGF-1: Insulin-lik
2 Change expressed as the difference between week 3 and week 10 absolute value
3 Week 3 values significantly (P < 0.05) different from week 10 values within groupdaily calorie deficit relative to the IFCR-F group (453
kcal/d, 250 kcal/d, respectively). These decreases in waist
circumference in the IFCR-L group were related to
reductions in LDL cholesterol concentrations. An accu-
mulation of adipose tissue in visceral depots may con-
tribute to the development of dyslipidemia in several
ways. For instance, lipolysis of fat tissue in visceral adi-
pocytes is higher than that of subcutaneous adipocytes.
This can lead to an augmented efflux of FFA from vis-
ceral depots [20]. These FFAs released from visceral fat
are then collected by the portal vein and reach the liver
at much higher concentrations than they do the systemic
circulation [20]. In the liver, these FFA trigger the aug-
mented production of triglycerides, and the elevated se-
cretion of VLDL [20]. The increased secretion of VLDL
then results in higher plasma levels of LDL [20]. In view
of this, it is conceivable that the decrease in visceral fat1
IFCR-F
Change 2 Week 3 Week 10 Change 2
−9.4 ± 1.6 37.6 ± 2.5 29.4 ± 2.4 3 −8.2 ± 1.7
−0.6 ± 0.3 3.1 ± 0.4 3.3 ± 0.4 0.2 ± 0.4
−0.4 ± 0.1 1.2 ± 0.3 1.1 ± 0.2 −0.1 ± 0.1
0 ± 0.1 0.6 ± 0.2 0.4 ± 0.1 −0.2 ± 0.2
0.1 ± 0.1 1.8 ± 0.1 1.9 ± 0.1 0.1 ± 0.1
−6.9 ± 2.3 69.6 ± 3.8 67.6 ± 5.4 −2.0 ± 4.9
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concentrations shown here.
Decreases in pro-atherogenic adipokines, such as leptin
(26%), IL-6 (19%), TNF-alpha (25%), and IGF-1 (10%)
were observed by the IFCR-L group. No changes in adi-
pokines were noted in the IFCR-F group, however, which
is most likely due to insufficient weight loss to achieve
changes in these parameters [21]. The decreases in leptin
noted here are similar to those observed by Harvie et al.
[2]. After 24 weeks of IF, obese women experienced
potent reductions in leptin of 40% [2]. The greater reduc-
tions in leptin in this previous trial are most likely due to
the greater weight loss achieved with the longer trial dur-
ation [22]. In the IFCR-L group, lower plasma leptin was
related to decreased triglyceride levels. In vitro studies
demonstrate that leptin is a potent stimulator of lipolysis
and fatty acid oxidation in adipocytes and other cell types
[23]. Accordingly, leptin is also a regulator of circulating
triacylglycerol concentrations [23]. Reduced leptin levels
were also related to lower LDL cholesterol levels post-
treatment, though the mechanism by which leptin may
be involved in reducing LDL cholesterol concentrations
is not clear. We also observed a positive association be-
tween visceral fat mass and leptin levels. Thus, it is pos-
sible that the decrease in visceral fat by the IFCR-L
intervention stimulated a reduction in leptin, which in
turn contributed to the lipid profile improvements
demonstrated here. Reductions in TNF-alpha were
also correlated to decreases in plasma triglycerides.
Evidence in rodent models indicates that TNF-alpha
induces hyperlipidemia by increasing hepatic triglycer-
ide production [24]. Thus, a reduction in circulating
TNF-alpha by IFCR-L may be related to the reduc-
tions in triglycerides observed.
This study is limited in that it did not carefully control
for food intake by providing food-based meals to the inter-
vention groups, i.e. dinner meal for the IFCR-L group, and
3 meals/d for the IFCR-F group. Providing all the meals
during the study would allow for a more precise assess-
ment of dietary adherence. Another disadvantage is that
only female subjects were employed, and as such, the ap-
plicability of these findings to males remains uncertain.
Taken together, our results suggest that IFCR with liquid
meals is an effective diet therapy to reduce body weight,
visceral fat mass, and lipid indicators of CHD risk. Our
findings also demonstrate that the beneficial modulations
in vascular disease risk by IFCR may be mediated, in part,
by reductions in visceral fat mass and pro-atherogenic adi-
pokines. This study is an important first step to under-
standing the underlying mechanisms that mediate the
cardio-protective effects of this novel diet regimen.
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